Thus, in a potential real clinical scenario, ctDNA-associated rechallenge with EGFR inhibitors could be considered following progression to trifluridine-tipiracil plus bevacizumab or an option as third-line treatment if tumor shrinkage is required. The gene discussed is EGFR; the disease is neoplasm.